Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Epax Norway AS is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single active matter suggests a highly specific focus for the company's current intellectual property efforts. The presence of 1 pending action indicates that the company is likely prioritizing a particular biotechnological advancement at this time.
The prosecution is overseen by 1 distinct examiner and 1 distinct art unit. This alignment between the examiner and the art unit reflects a concentrated examination process with no technical fragmentation. For the company, this means that the entirety of its active patent strategy is currently subject to the review of a single individual within a single specialized unit. The use of 1 distinct art unit implies a narrow technical scope for the current filing.
WHITE, DAWANNA SHAR-DAY is the busiest examiner for this portfolio, currently handling 1 busiest examiner pending action. Since this examiner manages the only active case, their individual history and interpretation of the prior art will determine the outcome of the company's current filing. The concentration of 1 busiest examiner pending action under one examiner allows for a focused advocacy strategy but places significant weight on a single relationship.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WHITE, DAWANNA SHAR-DAY | 1 | 62.4% | +24.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17311600 | VERY LONG CHAIN FATTY ACID COMPOSITIONS | WHITE, DAWANNA SHAR-DAY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17311600 | VERY LONG CHAIN FATTY ACID COMPOSITIONS | WHITE, DAWANNA SHAR-DAY | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17311600 | VERY LONG CHAIN FATTY ACID COMPOSITIONS | WHITE, DAWANNA SHAR-DAY | 1627 | §101 | Final Rejection | — | Pending | Jun 07, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEpax Norway AS has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Dawanna Shar-Day White has the most, with 1 of Epax Norway AS's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
